Eli Lilly's once-weekly insulin, efsitora alfa, demonstrated comparable efficacy to daily insulins in two Phase 3 trials.

Eli Lilly's once-weekly insulin, efsitora alfa, has shown comparable efficacy in reducing blood sugar levels to daily insulins in two Phase 3 trials, QWINT-1 and QWINT-3. Efsitora achieved a 1.31% reduction in A1C after 52 weeks, similar to 1.27% for daily insulin glargine. The safety profile was comparable, with slightly fewer severe hypoglycemia events. The announcement led to a 2.25% drop in Lilly's stock price.

September 05, 2024
17 Articles